Benchmark Holdings PLC Notice of Q4 and Full Year Results (4997S)
November 06 2023 - 5:24AM
UK Regulatory
TIDMBMK
RNS Number : 4997S
Benchmark Holdings PLC
06 November 2023
6 November 2023
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Notice of Q4 and Full Year Results
Webcast for analysts and institutional investors
Equity Development webcast for retail investors
Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK),
the aquaculture biotechnology business, will announce its Q4 and
Full Year results, for the 12 month period ended 30 September 2023,
on Wednesday 29(th) November 2023.
Presentation for analysts and institutional investors at 8am
GMT
Trond Williksen, Chief Executive Officer and Septima Maguire,
Chief Financial Officer will host a presentation for analysts and
institutional investors on the day at 08.00 GMT (09.00 CET).
The presentation will be held in person at Haakon Vlls Gate 2,
Oslo, Norway. To register your interest, please contact
benchmark@mhpgroup.com
A live webcast of the presentation will be available for
analysts and investors to join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20231129_1
Equity Development webcast for retail investors at 12pm GMT
Trond Williksen, Chief Executive Officer and Septima Maguire,
Chief Financial Officer will host a second webcast for retail
investors and wealth managers at 12.00 GMT (13:00 CET). The webcast
is open to all existing and potential shareholders.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-29november2023
Enquiries
For further information, please contact:
Benchmark Holdings plc Tel: 0114 240 9939
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Deutsche Numis (Nominated Adviser and Tel: 020 7260 1000
Broker)
Freddie Barnfield, Duncan Monteith, Sher
Shah
MHP Tel: 020 3128 8004
Katie Hunt, Reg Hoare benchmark@mhpgroup.com
Equity Development Tel: 020 7065 2692
Hannah Crowe
About Benchmark
Benchmark is a leading aquaculture biotechnology company.
Benchmark's mission is to enable aquaculture producers to improve
their sustainability and profitability.
We bring together biology and technology to develop innovative
products and solutions which improve yield, quality and animal
health and welfare for our customers. We do this by improving the
genetic make-up, health and nutrition of their stock - from
broodstock and hatchery through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), specialist diets and
probiotics and sea lice treatments. Find out more at
www.benchmarkplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFLFLILVLRIIV
(END) Dow Jones Newswires
November 06, 2023 05:24 ET (10:24 GMT)
Benchmark (LSE:BMK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Benchmark (LSE:BMK)
Historical Stock Chart
From Jul 2023 to Jul 2024